Home

Marsha Fanucci

CIK 1298814 · SVP, Chief Financial Officer · last filed 2026-03-02

Marsha Fanucci is a SVP, Chief Financial Officer who has filed 71 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for GENB, was dated Mar 2, 2026. Across all open-market trades the lifetime net is −$9.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $552.2K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$552.2K

Companies

8

Total Filings

71

Lifetime Open-Market Net

-$9.70M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GENB Director — $12.96 — $0 1 2026-03-02
Syros Pharmaceuticals, Inc. (SYRS) Delisted Director 16,000 $0.00 $6 $0 11 2024-06-07
ALNY Director 136 $287.80 $39.1K -$8.45M 18 2023-05-19
Forma Therapeutics Holdings, Inc. (FMTX) Delisted Director 0 $20.01 $0 $0 5 2022-10-14
CYCN Director 848 $3.55 $3.0K $0 6 2022-06-16
IRWD Director 132,663 $3.85 $510.1K -$243.9K 9 2019-04-03
MOMENTA PHARMACEUTICALS INC (MNTA) Delisted Director 14,500 — — -$416.0K 11 2016-06-27
MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted SVP, Chief Financial Officer 5,217 — — -$590.6K 9 2008-05-15

Recent Filings

71 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-02 GENB Grant (A) — $0 EDGAR
2025-03-14 — Notice (144) −9,333 -$924 EDGAR
2024-06-07 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) +4,000 $0 EDGAR
2023-06-02 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) +4,000 $0 EDGAR
2023-05-19 ALNY Grant (A) — $0 EDGAR
2023-02-27 ALNY Exer (M) +136 $0 EDGAR
2022-10-14 Forma Therapeutics Holdings, Inc. (FMTX) Delisted Mixed −59,782 $0 EDGAR
2022-09-19 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) +8,000 $0 EDGAR
2022-06-16 CYCN Grant (A) — $0 EDGAR
2022-06-09 Forma Therapeutics Holdings, Inc. (FMTX) Delisted Grant (A) +4,500 $0 EDGAR
Showing 1–10 of 71
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.